Financhill
Sell
48

NNVC Quote, Financials, Valuation and Earnings

Last price:
$1.24
Seasonality move :
6.37%
Day range:
$1.23 - $1.33
52-week range:
$1.03 - $3.59
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.97x
Volume:
175.9K
Avg. volume:
258.6K
1-year change:
9.17%
Market cap:
$20.5M
Revenue:
--
EPS (TTM):
-$0.72

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
NNVC
Nanoviricides
-- -$0.20 -- -26.67% --
ATNM
Actinium Pharmaceuticals
-- -$0.39 -100% -22.58% $5.00
NBY
NovaBay Pharmaceuticals
$2.5M -$0.24 14.03% -95.43% $0.85
OGEN
Oragenics
-- -- -- -- $1.00
PTN
Palatin Technologies
-- -$0.42 -100% -67.93% $7.00
TOVX
Theriva Biologics
-- -$5.50 -- -8.25% $6.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
NNVC
Nanoviricides
$1.31 -- $20.5M -- $0.00 0% --
ATNM
Actinium Pharmaceuticals
$1.30 $5.00 $40.6M -- $0.00 0% --
NBY
NovaBay Pharmaceuticals
$0.64 $0.85 $3.1M -- $0.00 0% 0.07x
OGEN
Oragenics
$0.27 $1.00 $3.3M -- $0.00 0% 1.05x
PTN
Palatin Technologies
$0.81 $7.00 $21.1M -- $0.00 0% --
TOVX
Theriva Biologics
$1.19 $6.00 $3.3M -- $0.00 0% 1.59x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
NNVC
Nanoviricides
-- 1.325 -- --
ATNM
Actinium Pharmaceuticals
-- -1.121 -- 9.03x
NBY
NovaBay Pharmaceuticals
4.54% 0.646 1.51% 0.75x
OGEN
Oragenics
-- 3.509 -- --
PTN
Palatin Technologies
-- -1.737 -- 0.99x
TOVX
Theriva Biologics
-- -2.868 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
NNVC
Nanoviricides
-- -$2.1M -- -- -- -$2.2M
ATNM
Actinium Pharmaceuticals
-- -$12.6M -95.08% -95.08% -12769.14% -$12M
NBY
NovaBay Pharmaceuticals
$1.6M -$1.1M -334.47% -461.38% -44% -$2.1M
OGEN
Oragenics
-- -$2.4M -- -- -- -$2M
PTN
Palatin Technologies
-- -$5.1M -- -- -2356.3% -$4.8M
TOVX
Theriva Biologics
-- -$4.6M -- -- -- -$4.7M

Nanoviricides vs. Competitors

  • Which has Higher Returns NNVC or ATNM?

    Actinium Pharmaceuticals has a net margin of -- compared to Nanoviricides's net margin of -11511.11%. Nanoviricides's return on equity of -- beat Actinium Pharmaceuticals's return on equity of -95.08%.

    Company Gross Margin Earnings Per Share Invested Capital
    NNVC
    Nanoviricides
    -- -$0.14 --
    ATNM
    Actinium Pharmaceuticals
    -- -$0.37 $36.4M
  • What do Analysts Say About NNVC or ATNM?

    Nanoviricides has a consensus price target of --, signalling upside risk potential of 396.18%. On the other hand Actinium Pharmaceuticals has an analysts' consensus of $5.00 which suggests that it could grow by 284.62%. Given that Nanoviricides has higher upside potential than Actinium Pharmaceuticals, analysts believe Nanoviricides is more attractive than Actinium Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    NNVC
    Nanoviricides
    0 0 0
    ATNM
    Actinium Pharmaceuticals
    2 1 0
  • Is NNVC or ATNM More Risky?

    Nanoviricides has a beta of 1.142, which suggesting that the stock is 14.225% more volatile than S&P 500. In comparison Actinium Pharmaceuticals has a beta of 0.105, suggesting its less volatile than the S&P 500 by 89.517%.

  • Which is a Better Dividend Stock NNVC or ATNM?

    Nanoviricides has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Actinium Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nanoviricides pays -- of its earnings as a dividend. Actinium Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios NNVC or ATNM?

    Nanoviricides quarterly revenues are --, which are smaller than Actinium Pharmaceuticals quarterly revenues of $81K. Nanoviricides's net income of -$2M is higher than Actinium Pharmaceuticals's net income of -$11.6M. Notably, Nanoviricides's price-to-earnings ratio is -- while Actinium Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nanoviricides is -- versus -- for Actinium Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NNVC
    Nanoviricides
    -- -- -- -$2M
    ATNM
    Actinium Pharmaceuticals
    -- -- $81K -$11.6M
  • Which has Higher Returns NNVC or NBY?

    NovaBay Pharmaceuticals has a net margin of -- compared to Nanoviricides's net margin of -49.65%. Nanoviricides's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    NNVC
    Nanoviricides
    -- -$0.14 --
    NBY
    NovaBay Pharmaceuticals
    65.26% -$0.60 $1.1M
  • What do Analysts Say About NNVC or NBY?

    Nanoviricides has a consensus price target of --, signalling upside risk potential of 396.18%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 31.89%. Given that Nanoviricides has higher upside potential than NovaBay Pharmaceuticals, analysts believe Nanoviricides is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    NNVC
    Nanoviricides
    0 0 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is NNVC or NBY More Risky?

    Nanoviricides has a beta of 1.142, which suggesting that the stock is 14.225% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.726, suggesting its less volatile than the S&P 500 by 27.362%.

  • Which is a Better Dividend Stock NNVC or NBY?

    Nanoviricides has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nanoviricides pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios NNVC or NBY?

    Nanoviricides quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Nanoviricides's net income of -$2M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Nanoviricides's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nanoviricides is -- versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NNVC
    Nanoviricides
    -- -- -- -$2M
    NBY
    NovaBay Pharmaceuticals
    0.07x -- $2.4M -$1.2M
  • Which has Higher Returns NNVC or OGEN?

    Oragenics has a net margin of -- compared to Nanoviricides's net margin of --. Nanoviricides's return on equity of -- beat Oragenics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    NNVC
    Nanoviricides
    -- -$0.14 --
    OGEN
    Oragenics
    -- -$0.38 --
  • What do Analysts Say About NNVC or OGEN?

    Nanoviricides has a consensus price target of --, signalling upside risk potential of 396.18%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 273.13%. Given that Nanoviricides has higher upside potential than Oragenics, analysts believe Nanoviricides is more attractive than Oragenics.

    Company Buy Ratings Hold Ratings Sell Ratings
    NNVC
    Nanoviricides
    0 0 0
    OGEN
    Oragenics
    0 1 0
  • Is NNVC or OGEN More Risky?

    Nanoviricides has a beta of 1.142, which suggesting that the stock is 14.225% more volatile than S&P 500. In comparison Oragenics has a beta of 0.847, suggesting its less volatile than the S&P 500 by 15.305%.

  • Which is a Better Dividend Stock NNVC or OGEN?

    Nanoviricides has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nanoviricides pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios NNVC or OGEN?

    Nanoviricides quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. Nanoviricides's net income of -$2M is higher than Oragenics's net income of -$2.5M. Notably, Nanoviricides's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nanoviricides is -- versus 1.05x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NNVC
    Nanoviricides
    -- -- -- -$2M
    OGEN
    Oragenics
    1.05x -- -- -$2.5M
  • Which has Higher Returns NNVC or PTN?

    Palatin Technologies has a net margin of -- compared to Nanoviricides's net margin of -2357.27%. Nanoviricides's return on equity of -- beat Palatin Technologies's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    NNVC
    Nanoviricides
    -- -$0.14 --
    PTN
    Palatin Technologies
    -- -$0.12 -$111.5K
  • What do Analysts Say About NNVC or PTN?

    Nanoviricides has a consensus price target of --, signalling upside risk potential of 396.18%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 764.09%. Given that Palatin Technologies has higher upside potential than Nanoviricides, analysts believe Palatin Technologies is more attractive than Nanoviricides.

    Company Buy Ratings Hold Ratings Sell Ratings
    NNVC
    Nanoviricides
    0 0 0
    PTN
    Palatin Technologies
    0 0 0
  • Is NNVC or PTN More Risky?

    Nanoviricides has a beta of 1.142, which suggesting that the stock is 14.225% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.793, suggesting its less volatile than the S&P 500 by 20.66%.

  • Which is a Better Dividend Stock NNVC or PTN?

    Nanoviricides has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nanoviricides pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios NNVC or PTN?

    Nanoviricides quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Nanoviricides's net income of -$2M is higher than Palatin Technologies's net income of -$2.4M. Notably, Nanoviricides's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nanoviricides is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NNVC
    Nanoviricides
    -- -- -- -$2M
    PTN
    Palatin Technologies
    -- -- $350K -$2.4M
  • Which has Higher Returns NNVC or TOVX?

    Theriva Biologics has a net margin of -- compared to Nanoviricides's net margin of --. Nanoviricides's return on equity of -- beat Theriva Biologics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    NNVC
    Nanoviricides
    -- -$0.14 --
    TOVX
    Theriva Biologics
    -- -$1.60 --
  • What do Analysts Say About NNVC or TOVX?

    Nanoviricides has a consensus price target of --, signalling upside risk potential of 396.18%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 404.2%. Given that Theriva Biologics has higher upside potential than Nanoviricides, analysts believe Theriva Biologics is more attractive than Nanoviricides.

    Company Buy Ratings Hold Ratings Sell Ratings
    NNVC
    Nanoviricides
    0 0 0
    TOVX
    Theriva Biologics
    0 0 0
  • Is NNVC or TOVX More Risky?

    Nanoviricides has a beta of 1.142, which suggesting that the stock is 14.225% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.159, suggesting its more volatile than the S&P 500 by 15.945%.

  • Which is a Better Dividend Stock NNVC or TOVX?

    Nanoviricides has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nanoviricides pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios NNVC or TOVX?

    Nanoviricides quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Nanoviricides's net income of -$2M is higher than Theriva Biologics's net income of -$4.4M. Notably, Nanoviricides's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nanoviricides is -- versus 1.59x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NNVC
    Nanoviricides
    -- -- -- -$2M
    TOVX
    Theriva Biologics
    1.59x -- -- -$4.4M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is the Market Going to Go Lower?
Is the Market Going to Go Lower?

The last month has been extremely difficult for the stock…

2 Dividend Stocks to Buy in a Recession
2 Dividend Stocks to Buy in a Recession

While many economists and investors initially expected 2025 to be…

Is Ford Stock Undervalued Amid the EV Transition?
Is Ford Stock Undervalued Amid the EV Transition?

There is a lot going on in the electric vehicle…

Stock Ideas

Buy
53
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Sell
48
SMTC alert for Mar 18

Semtech [SMTC] is down 1.95% over the past day.

Buy
67
PLPC alert for Mar 18

Preformed Line Products [PLPC] is up 1.08% over the past day.

Buy
58
NUTX alert for Mar 18

Nutex Health [NUTX] is down 3.64% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock